Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8333-8346
DOI: 10.1007/s00259-026-08056-1 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.08.2026. Verfasst von Luca Urso und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Via Aldo Moro N.8, Ferrara, Italy. luca.urso@unife.it. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Ferrara.
Abstract (Originalsprache)
Purpose
Triple negative breast cancer (TNBC) is an aggressive subtype, still with limited therapeutic options. [ 18 F]FDG PET/CT is widely used in TNBC, but evidence regarding its prognostic value remains limited. The TRINE PET study, promoted by the Italian Association of Nuclear Medicine, aimed to evaluate the prognostic relevance and clinical impact of [ 18 F]FDG PET/CT in a large real world TNBC cohort.
Methods
This retrospective multicenter study included 389 TNBC patients who underwent 707 [ 18 F]FDG PET/CT scans across 23 Italian Nuclear Medicine Units. Clinical settings were baseline staging ( n = 257 patients), post neoadjuvant chemotherapy ( n = 111 patients), suspected recurrence ( n = 144 patients), and advanced metastatic disease ( n = 195 patients). Progression free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier and Cox regression analyses. The influence of [ 18 F]FDG PET/CT on clinical management was evaluated across all settings.
Results
During a median follow up of 34 months (1–124), disease progression and death occurred in 39.3% and 28.4% of cases, respectively. Across all clinical settings, nodal and distant metastatic involvement at [ 18 F]FDG PET/CT was strongly associated with worse PFS and OS (all p < 0.001). In multivariate analysis, distant metastases at [ 18 F]FDG PET/CT resulted the strongest independent predictor of OS (HR 9.42, 95% CI 3.74–23.75) and PFS (HR 6.57, 95% CI 3.05–14.12), while Ki67 and [ 18 F]FDG uptake at primary tumor did not. [ 18 F]FDG PET/CT findings led to a change in clinical management in 20.8% of all scans, with the highest impact in the advanced metastatic setting (34.9%).
Conclusion
In the largest real world multicenter study dedicated to TNBC, [ 18 F]FDG PET/CT demonstrated robust prognostic value across all disease settings. PET detected metastatic involvement emerged as the most powerful predictor of survival; moreover, [ 18 F]FDG PET/CT influenced therapeutic decision in all settings of disease, reaching one in three scans in the advanced metastatic disease. These findings support the systematic integration of [ 18 F]FDG PET/CT into the diagnostic pathways of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, Via Aldo Moro N.8, Ferrara, Italy. luca.urso@unife.it.
- Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy. luca.urso@unife.it.
- Nuclear Medicine Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy.
- Nuclear Medicine, University of Brescia, Brescia, Italy.
- Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
- Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Förderung
- Università degli Studi di Ferrara
Zitieren
APA
Urso, L., Panareo, S., Albano, D., Iudicello, A., Filippi, L., Borgia, F., Bartolomei, M., Guglielmo, P., Bertagna, F., Taralli, S., Calcagni, M. L., Mazzoletti, A., Bonacina, M., Fantini, L., Paccagnella, A., Colombo, C. B., Castellani, M., Annovazzi, A., Sciuto, R., …, & All the TRINE-PET Investigators (2026). Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8333-8346. https://doi.org/10.1007/s00259-026-08056-1
Vancouver
Urso L, Panareo S, Albano D, Iudicello A, Filippi L, Borgia F, et al. Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8333-8346. doi:10.1007/s00259-026-08056-1
BibTeX
@article{Urso2026,
author = {Urso, Luca and Panareo, Stefano and Albano, Domenico and Iudicello, Antonella and Filippi, Luca and Borgia, Francesca and Bartolomei, Mirco and Guglielmo, Priscilla and Bertagna, Francesco and Taralli, Silvia and Calcagni, Maria Lucia and Mazzoletti, Angelica and Bonacina, Mattia and Fantini, Lorenzo and Paccagnella, Andrea and Colombo, Carlotta Benedetta and Castellani, Massimo and Annovazzi, Alessio and Sciuto, Rosa and Bauckneht, Matteo and Garrou, Federico and Aricò, Demetrio and Rovera, Guido and Ferrari, Cristina and Miceli, Alberto and Reccia, Pasquale and Cassarino, Gianluca and Rizza, Elisa and Marongiu, Andrea and Arnone, Annachiara and Maffione, Anna Margherita and Ialuna, Salvatore and Frega, Nicola and Evangelista, Laura and All the TRINE-PET Investigators, All the TRINE-PET Investigators},
title = {Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8333--8346},
doi = {10.1007/s00259-026-08056-1}
}
EUVIMED